Mice were infected with Ad5 (empty) or Ad5-ATP8b1 (n=3-4 group) and then inoculated with 1 x 10 6 CFU E. coli or uninfected for 48 h. BAL were collected and centrifuged. a) Cell counts in ATP8b1 overexpressing mice. Cells from pellets were resuspended in Hanks BSS and 1 x 10 5 cells were Cytospun onto slides and stained with Wright-Giemsa stain for differential cell counting. Mono/Macs and Neutrophils: ***P<0.001 for comparisons between empty vs. empty + E. coli, empty vs. ATP8b1 + E. coli, ATP8b1 vs. ATP8b1 + E. coli. b) BAL protein in ATP8b1 overexpressing mice. BAL supernatants were assayed for protein concentration using a Lowry assay. c) 0.5% fatty-acid free BSA plus EDTA-free protease inhibitor cocktail was added to the supernatant and assayed for cytokines with a Bio-Plex Mouse Assay 8-Plex Group 1 kit (BioRad). **P<0.01 for IL-1 empty vs. IL-1 + E. coli, TNF empty + E. coli vs. TNF ATP8b1, ***P<0.001 for TNF empty vs. TNF empty + E. coli. d) Surfactant proteins in the lungs were assayed by immunoblotting using SP-A, SP-B, SP-D antibodies from Millipore and SP-C from ABCAM. Densitometry of three to five separate experiments was performed and expressed as fold change from control ( -actin). *P<0.05 vs. control. e) Lung mechanics in ATP8b1 overexpressing mice. Mice (n=8/group) received an empty vector (Ad5) or Ad5-ATP8b1 (2.5 x 10 8 PFU) i.t. and 24 h later given E. coli at 10 6 CFU/mouse for 48 h. Animals were anesthetized, paralyzed and mechanically ventilated and lung resistance determined as in Fig. 2 . Significance was determined by a one-way ANOVA where *P<0.05 for Ad5 + E. coli vs. Ad5-ATP8b1, **P<0.01 for Ad5 + E. coli vs. Ad5-ATP8b1+ E. coli. Figure 5 . BAL proteins and cell counts, lung edema and bacterial load in ATP8b1 defective mice. a) Bacterial loads in ATP8b1 defective mice. ATP8b1 mutant (MUT) mice and wild-type (WT) littermates (n=4 group) (129S strain) were inoculated with 1 x 10 6 CFU E. coli. Lungs were lavaged with PBS after 48 h, lungs resected and homogenized. BAL supernatants and lung homogenates were diluted and plated on TSB agar plates to determine colony forming units (CFU). b) BAL protein in ATP8b1 defective mice. BAL supernatants from MUT and WT mice (6 per group), were assayed for protein concentration using a Lowry assay. *P<0.05 for WT vs WT + E. coli, and MUT vs. MUT+ E. coli, **P<0.01 for MUT vs WT+ E. coli. c) Lung edema in ATP8b1 defective mice. ATP8b1 mutant (MUT) mice and wild-type (WT) littermates (n=4 mice/group) were inoculated with 1 x 10 6 CFU E. coli or uninfected for 48 h. Lungs were removed after 48 hr, blotted, and placed in tared weigh boats and weighed. The lungs were then dried for 24 h at 60 °C in the same weigh boats and weighed again. d) Cell counts in ATP8b1 defective mice. BAL from MUT and WT (n=6 per group) were collected and centrifuged. Cells from pellets were resuspended in Hanks BSS and 1 x 10 5 cells were Cyto-spun onto slides and stained with Wright-Giemsa stain for differential cell counting. *P<0.05 vs. uninfected groups. Mice were inoculated with 1 x 10 6 CFU E. coli or uninfected for 48 h prior to i.t. administration of various amounts of CBD. BAL were collected and centrifuged. Cells from pellets were resuspended in Hanks BSS and 1 x 10 5 cells were Cyto-spun onto slides and stained with Wright-Giemsa stain for differential cell counting. Mono/Macs and Neutrophils: ***P<0.001 for control (0-) vs. vehicle buffer (0+), 25 μg CBD, 100 μg CBD, or 250 μg CBD. b) BAL protein in mice given CBD peptide. Mice (n=5-6 mice/ group) were infected with E. coli at 10 6 CFU/mouse. After 48 h, mice were given CBD (50 nmol, i.t.) for 1 h. BAL supernatants were assayed for protein concentration using a Lowry assay. **P<0.01 for vehicle buffer (0+) vs. 25 μg CBD and 250 μg CBD. c) Cytokines in mice given CBD peptide. Mice (n=4/group) were inoculated with 1 x 10 6 CFU E. coli or uninfected for 48 h prior to i. 
Analysis of cardiolipin in BAL.
Total lipids were extracted from BAL using the method described by Bligh and Dyer (1). Lipid extracts were separated and analyzed by 2D-HPTLC (2). Total lipids (60 nmol) were applied onto and the plates were first developed with a solvent system consisting of chloroform: methanol: 28% ammonium hydroxide (65:25:5 v/v). After the plates were dried with a forced N 2 blower to remove the solvent, they were developed in the second dimension with a solvent system consisting of chloroform:acetone:methanol:glacial acetic acid:water (50:20:10:10:5 v/v). The phospholipids were visualized by exposure to iodine vapors and identified by comparison with authentic phospholipid standards. Lipid phosphorus was determined by a micro-method (3). LC/ESI-MS was performed using a Dionex Ultimate TM 3000 HPLC coupled on-line to ESI and a linear ion trap mass spectrometer (LXQ Thermo-Fisher). The lipids were separated on a normal phase column (Luna 3 m Silica 100A, 150x2 mm, (Phenomenex, Torrance CA)) with flow rate 0.2 mL/min using gradient solvents A and B. Solvent A was chloroform/methanol/28% ammonium hydroxide, 80:19.5:0.5 (v/v). Solvent B was chloroform/methanol/water/28% ammonium hydroxide, 60:34:5:0.5 (v/v). The column was eluted during the first 3 min isocratic at 0% solvent B, 3-20 min with a linear gradient from 0% solvent B to 100% solvent B, and then 20-23 min isocratic at 100% solvent B, 23-35 min linear gradient to 0% solvent B, 35-40 min isocratic at 0% solvent B for equilibrium column (4). The spectra of CL were acquired in negative mode and the scan data type was set to centroid. 
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a b Methods
ATP8b1 expression and cloning. Real-time PCR was performed as described 33 . Total RNA was isolated from murine small intestinal mucosal cells using Tri reagent (Sigma), reverse transcribed to cDNA, and ATP8b1 amplified using an Accuscript kit (Stratagene) with ATP8b1 primers. A 4.0 kb fragment of DNA including the full-length coding sequence and the stop codon for ATP8b1 was cloned into the pENTR/D-TOPO followed by pcDNA-DEST40, pLenti6/V5-DEST, or pcDNA3.1D/V5-His (Invitrogen Gateway Cloning System). A full-length (FL) ATP8b1/ pcDNA-DEST40 clone was used to generate truncation mutants by site-directed mutagenesis using a Quik-Change II kit (Stratagene), by introduction of stop codons. NH 2 -terminal deletion mutants were generated by PCR using 5' primers introducing start codons within the ATP8b1 primary sequence. PCR products were cloned into pENTR/D-TOPO followed by pcDNA-DEST40.
ATP8b1 CL binding domain (CBD) peptide. The ATP8b1 CL binding domain (CBD) peptide (amino acids 771-850) was amplified from FL ATP8b1 in pcDNA-DEST40 with engineered BamHI sites and ligated to a GST containing fragment excised from pDEST26 (Invitrogen) using BlgII. GST-CBD or GST alone were then cloned into pcDNA3.1D/V5-His (Invitrogen) and transfected into MLE cells for expression and GST pull-downs, or used for in vitro transcription and translation (TnT) 33 .
Confocal microscopy. Frozen lung sections fixed (2% paraformaldehyde), permeabilized with 0.1% saponin, and incubated with the primary antibodies or mouse anti-occludin followed by AlexaFlour 568 goat anti-rabbit and AlexaFluor488 chicken anti-mouse secondary antibodies, respectively (Invitrogen). Preparations were imaged using a Zeiss 510 Multiphoton/Confocal microscope (Bio-Rad).
In vitro translation. A TNT T7 coupled reticulocyte lysate system kit (Promega) including T7 polymerase and rabbit reticulocyte lysate was used for in vitro protein expression of 35 S-methionelabeled ATP8b1 FL, NH 2 -terminal mutants, and ATP8b1 CBD and GST peptide clones 33 .
In vivo micro-CT imaging. Lipid (CL [50 nmol, 100 nmol]) was administered through a tracheotomy, mice paralyzed, and sedation maintained during mechanical ventilation using 1.5% isofluorane. A Micro-CT II (Siemens Pre-Clinical Solutions) was used for in vivo scanning using a custom gated imaging process with settings of 60kVp, 500microA, and an exposure time of 500ms. A total of 720 projections were acquired over 200 degrees.
Tissue fixation. Lungs were fixed using 25% polyethylene glycol 400, 10% ethyl alcohol, 10% formaldehyde i.t. via a gravity feed system at a constant pressure (20 cmH 2 O). After 30 min., lungs were removed and immersed in fixative solution for 24 h., Lungs were then air-dried for 48 h at 60 °C with 20 cmH 2 O air pressure applied at the trachea. Ex vivo imaging was acquired at 60kVp, 368 microA and an exposure of 2250 ms. A total of 720 projections were acquired over 200 degrees.
Lipid overlay. Lipid strips (Echelon Biosciences, Inc.) were incubated with translation products in TTBS buffer with 1% fatty acid-free BSA. Strips were washed extensively and radiolabeled protein was detected with V5 antibody using immunoblotting.
Surface Tension. Required amounts of phospholipids (Avanti Polar Lipids, Inc.) dissolved in ethanol were dried under nitrogen. 0.25 ml of CaCl 2 (5 mM) solution containing 1 μmole Infasurf was added and sonicated for 10 s to incorporate the lipid into Infasurf. Apoprotein depletion was achieved by Bligh-Dyer extraction of Infasurf, reconstitution with individual phospholipids and CaCl 2 (5 mM), and shown to be devoid of SP-B and SP-C by immunoblotting. Dynamic minimum surface tension ( min ) was measured using a pulsating bubble surfactometer 34 .
